Biogen News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

27.11.20	Biogen, Sage Therapeutics To Jointly Develop And Commercialize Zuranolone, SAGE-324 (RTTNews)
27.11.20	Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders (GlobeNewswire)
18.11.20	Samsung Bioepis and Biogen Announce FDA Filing Acceptance of SB11, A Proposed Biosimilar Referencing Lucentis® (ranibizumab) (GlobeNewswire)
16.11.20	Biogen Ranked #1 Biotechnology Company by Dow Jones Sustainability World Index for an Industry Record 5th Time; Recognition Reflects Longstanding ESG Leadership (GlobeNewswire)
08.11.20	Week Ahead In Pharma: FDA Decisions, SITC Presentations, 13D SEC Filing (RTTNews)
07.11.20	Update on FDA Advisory Committee’s Meeting on Aducanumab in Alzheimer’s Disease (GlobeNewswire)
05.11.20	BIIB Faces FDA Panel Tomorrow, CRSP Climbs On Hemoglobinopathies Trial Data, SAVA On Watch (RTTNews)
03.11.20	Biogen to Present Positive Phase 2 Systemic Lupus Erythematosus Data at American College of Rheumatology 2020 Meeting (GlobeNewswire)
01.11.20	Week Ahead In Pharma: COVID-19 Data Readout, FDA Decisions, CTAD Presentation (RTTNews)
30.10.20	European Medicines Agency Accepts Biogen’s Aducanumab Marketing Authorization Application for Alzheimer's Disease (GlobeNewswire)
26.10.20	Biotech Stocks Facing FDA Decision In November 2020 (RTTNews)
21.10.20	Biogen Trims FY20 Earnings Outlook; Q3 Results Top Estimates - Quick Facts (RTTNews)
06.10.20	Samsung Bioepis and Biogen Announce EMA Filing Acceptance of SB11, a Proposed Biosimilar Referencing Lucentis® (ranibizumab) (GlobeNewswire)
14.09.20	Biogen Announces $250 Mln, 20-yr Initiative To Eliminate Fossil Fuels - Quick Facts (RTTNews)
14.09.20	Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health (GlobeNewswire)
11.09.20	New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen’s Industry-Leading MS Portfolio (GlobeNewswire)
08.09.20	New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS (GlobeNewswire)
07.08.20	Stock Alert: Biogen Ticking Up (RTTNews)
07.08.20	Biogen: FDA To Review Biologics License Application For Aducanumab (RTTNews)
07.08.20	FDA Accepts Biogen’s Aducanumab Biologics License Application for Alzheimer's Disease with Priority Review (GlobeNewswire)
06.08.20	Denali Stock Surges After Biogen Collaboration (RTTNews)
06.08.20	Biogen and Denali to Collaborate on LRRK2 Program for Parkinson’s Disease and Certain TV Platform-Enabled Programs for Neurodegenerative Diseases (GlobeNewswire)
24.07.20	Biogen to Present Data at Virtual 2020 Alzheimer’s Association International Conference Highlighting Comprehensive Approach to Alzheimer’s Disease (GlobeNewswire)
22.07.20	Biogen Boosts FY20 Earnings Outlook; Q2 Results Top Estimates - Quick Facts (RTTNews)
22.07.20	Biogen Appoints Michael McDonnell As EVP And CFO (RTTNews)
22.07.20	Biogen Names Michael McDonnell as Executive Vice President and Chief Financial Officer (GlobeNewswire)
21.07.20	Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated with Zolgensma® (onasemnogene abeparvovec) (GlobeNewswire)
08.07.20	The New England Journal of Medicine Publishes Final Results from Phase 1/2 Study of Tofersen for a Genetic Form of ALS (GlobeNewswire)
08.07.20	Stock Alert: Biogen Up 5%; Submits Application To FDA For Aducanumab (RTTNews)
08.07.20	Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer’s Disease (GlobeNewswire)
19.06.20	FDA Nod For EPZM, RARE, Court Rules In MYL's Favor, Ocuphire To Hop Onto Nasdaq, ALPN Soars (RTTNews)
18.06.20	Stock Alert: Biogen Tanks 6% (RTTNews)
10.06.20	Biogen: New Results From NURTURE Study Reveals Sustained Benefit Of SPINRAZA (RTTNews)
10.06.20	New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA® (nusinersen) Continue to Demonstrate Sustained Benefit From Treatment (GlobeNewswire)
04.06.20	Biogen Presents Positive Phase 2 Cutaneous Lupus Erythematosus (CLE) Data at European E-Congress of Rheumatology (EULAR) 2020 (GlobeNewswire)
28.05.20	Biogen and MIT Launch New Virtual Learning Lab for High School Students Historically Underrepresented in Science (GlobeNewswire)
19.05.20	New Data at AAN Showcase Biogen’s Commitment to Advancing Innovation in MS (GlobeNewswire)
18.05.20	New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients (GlobeNewswire)
27.04.20	Biogen Prices $3.0 Billion of Senior Unsecured Notes (GlobeNewswire)
22.04.20	Biogen Q1 Results Top Estimates - Quick Facts (RTTNews)
20.04.20	Biogen Releases 2019 Corporate Responsibility Report Demonstrating Continuous Progress Across Environmental, Social and Governance Metrics (GlobeNewswire)
16.04.20	Biogen, Broad Institute of MIT and Harvard, Partners HealthCare Launch Consortium to Build and Share a COVID-19 Biobank (GlobeNewswire)
02.04.20	Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study (GlobeNewswire)
27.02.20	Biogen, Sangamo Sign Deal To Develop Gene Therapies For Neurological Diseases (RTTNews)
27.02.20	Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological Diseases (GlobeNewswire)
18.02.20	Stock Alert: Warren Buffett's Berkshire Hathaway Reveals Stake In Kroger, Biogen (RTTNews)
30.01.20	Biogen Guides FY20 In Line With Estimates - Quick Facts (RTTNews)
30.01.20	Biogen Inc. Q4 adjusted earnings Beat Estimates (RTTNews)
13.01.20	Biogen To Acquire Clinical Stage PF-05251749 From Pfizer - Quick Facts (RTTNews)
13.01.20	Biogen to Acquire Novel Clinical Stage Asset with Application in Alzheimer’s Disease and Parkinson’s Disease from Pfizer Inc. (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

19.11.24		Schwacher Handel: Dow Jones legt am Dienstagnachmittag den Rückwärtsgang ein
19.11.24		Zurückhaltung in Frankfurt: SDAX beendet die Dienstagssitzung mit Verlusten
19.11.24		Schwache Performance in Europa: Euro STOXX 50 zeigt sich zum Handelsende schwächer
19.11.24		Schwacher Handel in Frankfurt: TecDAX schwächelt zum Handelsende
19.11.24		Schwacher Handel: SDAX fällt nachmittags
19.11.24		Minuszeichen in Frankfurt: TecDAX verbucht nachmittags Verluste
19.11.24		Bayer expandiert: Japan-Lizenz für potenzielles Herzmedikamentenkandidaten gesichert - Aktie tiefer
19.11.24		Dienstagshandel in Frankfurt: TecDAX präsentiert sich mittags leichter

19.11.24

Schwacher Handel: Dow Jones legt am Dienstagnachmittag den Rückwärtsgang ein

19.11.24

Zurückhaltung in Frankfurt: SDAX beendet die Dienstagssitzung mit Verlusten

19.11.24

Schwache Performance in Europa: Euro STOXX 50 zeigt sich zum Handelsende schwächer

19.11.24

Schwacher Handel in Frankfurt: TecDAX schwächelt zum Handelsende

19.11.24

Schwacher Handel: SDAX fällt nachmittags

19.11.24

Minuszeichen in Frankfurt: TecDAX verbucht nachmittags Verluste

19.11.24

Bayer expandiert: Japan-Lizenz für potenzielles Herzmedikamentenkandidaten gesichert - Aktie tiefer

19.11.24

Dienstagshandel in Frankfurt: TecDAX präsentiert sich mittags leichter

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	3’870.00	1.49 %	K V
Lonza Grp	513.60	1.14 %	K V
Swiss Re	125.25	0.20 %	K V
Holcim	88.46	0.11 %	K V
Kuehne+Nagel Int	210.40	0.00 %	K V
Logitech Intl	68.92	-1.20 %	K V
Part Grp Hldg	1’209.00	-1.47 %	K V
CieFinRichemont	118.90	-1.94 %	K V
Nestle	76.66	-1.94 %	K V
Sonova Hldg	300.40	-5.21 %	K V

Nachrichten zu Biogen Inc

Aktien Top/Flop

Biogen Peer Group Nachrichten

Meistgelesene Nachrichten